Press release - 01/09/2026 Early Detection of COPD: A Study in Freiburg Investigates a New Treatment Coughing, phlegm, and shortness of breath can be early signs of COPC. In COPD, the airways are permanently narrowed, making it harder to breathe. The most significant risk factor is long-term smoking. The CHRONOS study conducted by the Department of Pneumology at the Medical Center – University of Freiburg provides evidence that changes in the lungs can already be detected before a standard pulmonary function test confirms the airway narrowing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-detection-copd-study-freiburg-investigates-new-treatment
Event - 06/11/2026 Health Innovation Nexus Strasbourg, France, Registration deadline: 23/10/2026https://www.gesundheitsindustrie-bw.de/en/event/health-innovation-nexus-en
Press release - 28/08/2026 Outstanding success for Ulm’s quantum physics QuantERA funds four teams Research into quantum technology by four teams at Ulm University is being funded as part of the European QuantERA programme. This is more than at any other German university. The projects focus, for example, on more robust quantum computers and innovative medical diagnostic methods.https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-success-ulms-quantum-physics-quantera-funds-four-teams
Panosome GmbH – a parasite as the basis for innovative immunotherapies - 26/08/2026 Reaching the unreachable: new approaches to challenging drug targets Modern medicines act with remarkable precision. Antibodies, for example, recognise their molecular targets much like a key fits into its corresponding lock. However, certain targets like small molecules or carbohydrates remain difficult to target. The start-up Panosome aims to eliminate these blind spots with a novel immunotherapy platform that harnesses sophisticated masters of immune evasion: trypanosomes.https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-unreachable-new-approaches-challenging-drug-targets
Press release - 25/08/2026 Revier Therapeutics Launches with €6 Million Seed Financing to Pioneer Class IIa HDAC Inhibitors for Cardiometabolic Disease Revier Therapeutics, today announced the closing of a EUR 6 million seed financing and the launch of its operations. The Company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/revier-therapeutics-launches-euro-6-million-seed-financing-pioneer-class-iia-hdac-inhibitors-cardiometabolic-disease
Funding Next Frontier Robotics Competition, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 22/10/2026 https://www.gesundheitsindustrie-bw.de/en/database/funding/next-frontier-robotics-en
Event - 27/11/2026 Targeted Drug Delivery Ulm, Registration deadline: 20/11/2026, Kongress/Symposium https://www.gesundheitsindustrie-bw.de/en/event/targeted-drug-delivery-en